Dr. Joseph Kozikowski will present on the use of nanoscale molecular imaging in translational medicine at Hoffman-La Roche global headquarters.
FRAMINGHAM, MA – November 30, 2006 – Clinivation, Inc. announced today that clinivation Founder and CEO Joseph Kozikowski, M.D. will present to research and executive leadership at F. Hoffman-La Roche AG Pharmaceuticals global headquarters in Basel, Switzerland.
As an authority on the development and commercialization of advanced medical technology, Dr. Kozikowski will share his perspectives in a presentation entitled “Optimizing Development: Translational Validation of Breast Cancer Targets” on December 13, 2006.
The presentation will address Dr. Kozikowski’s translational research in nanoscale molecular imaging and cancer as Chief Medical Officer and Study Medical Director of ART Advanced Research Technologies Inc. (Technoparc Saint-Laurent, CAN).
Quotes & Commentary:
“It is an honor to have been invited to present, and I thank the Hoffman-La Roche executive leadership for their efforts in arranging this opportunity for learning,” said clinivation Founder and CEO Joseph Kozikowski, M.D.
About Hoffman La Roche:
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005 sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.
